1. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation
- Author
-
Mafalda Bacalhau, Carlos M. Farinha, Lúcia Santos, David J. Sanz, Miquéias Lopes-Pacheco, Karen Mention, Kader Cavusoglu-Doran, and Patrick T. Harrison
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,congenital, hereditary, and neonatal diseases and abnormalities ,Cystic Fibrosis ,CRISPR-Associated Proteins ,Nonsense mutation ,Nonsense-mediated decay ,Cystic Fibrosis Transmembrane Conductance Regulator ,medicine.disease_cause ,Cystic fibrosis ,Cell Line ,Homology directed repair ,03 medical and health sciences ,0302 clinical medicine ,Bacterial Proteins ,CRISPR-Associated Protein 9 ,Humans ,Medicine ,CRISPR ,Gene ,Gene Editing ,Mutation ,Endodeoxyribonucleases ,biology ,business.industry ,medicine.disease ,Molecular biology ,Cystic fibrosis transmembrane conductance regulator ,030104 developmental biology ,030228 respiratory system ,Pediatrics, Perinatology and Child Health ,biology.protein ,CRISPR-Cas Systems ,business - Abstract
Background W1282X-CFTR variant (c.3846G>A) is the second most common nonsense cystic fibrosis (CF)-causing mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Even though remarkable breakthroughs have been done towards CF treatment with the approval of four CFTR protein modulators, none of these are approved for patients with nonsense mutations. CRISPR gene editing tools can be of great value to permanently correct the genetic defects caused by these mutations. Methods We compared the capacity of homology-directed repair (HDR) mediated by Cas9 or Cas12a to correct W1282X CFTR mutation in the CFF-16HBEge W1282X CFTR cell line (obtained from CFF), using Cas9/gRNA and Cas12a/gRNA ribonucleoproteins (RNPs) and single strand DNA (ssODN) oligonucleotide donors. Results Cas9 shows higher levels of correction than Cas12a as, by electroporating cells with Cas9 RNPs and ssODN donor, nearly 18% of precise editing was achieved compared to just 8% for Cas12a. Such levels of correction increase the abundance of CFTR mRNA and protein, and partially restore CFTR function in the pool of edited cells to 18% of WT CFTR function. Moreover, homozygous corrected clones produced levels of mRNA, protein, and function comparable to those of cells expressing WT CFTR. Conclusion Altogether, this work demonstrates the potential of gene editing as a therapeutic strategy for CF directly correcting the root cause of the disease.
- Published
- 2022
- Full Text
- View/download PDF